5 results match your criteria: "Unidad de Esclerosis Múltiple. Hospital Universitario Son Espases[Affiliation]"
Early beginning of alemtuzumab: Changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study.
Neurologia (Engl Ed)
June 2024
Unidad de Esclerosis Múltiple. Hospital Universitario Son Espases, Palma de Mallorca, Spain.
Introduction: LEMVIDA is a real-world prospective study of 3-year follow-up on quality of life of patients with multiple sclerosis (MS) receiving alemtuzumab in Spain.
Methods: This is an interim analysis evaluating the baseline characteristics of patients who started alemtuzumab between October 2016-September 2018. For 3 additional subanalysis patients were categorised by baseline EDSS score; time of alemtuzumab initiation during the recruitment period (cohort 1: October 2016-March 2017, cohort 2: April-September 2017, cohort 3: October 2017-March 2018 and cohort 4: April-September 2018); and the presence of highly active MS criteria.
Consensus statement on the use of alemtuzumab in daily clinical practice in Spain.
Neurologia (Engl Ed)
October 2022
Centro de Esclerosis Múltiple de Cataluña (Cemcat), Servicio de Neurología/Neuroinmunología, Hospital Universitario Vall de Hebrón, Barcelona, Spain.
Introduction: Alemtuzumab is a highly effective drug approved by the European Medicines Agency as a disease-modifying drug for the treatment of relapsing-remitting multiple sclerosis.
Objective: A consensus document was drafted on the management of alemtuzumab in routine clinical practice in Spain.
Development: A group of multiple sclerosis specialists reviewed articles addressing treatment with alemtuzumab in patients with multiple sclerosis and published before December 2017.
SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry.
Neurol Neuroimmunol Neuroinflamm
July 2021
From the Centro de Esclerosis Múltiple de Cataluña (G.A.), (Cemcat), Instituto de Investigación Vall d'Hebron, Hospital Universitario Vall d'Hebron, Universidad Autónoma de Barcelona; Complejo Hospitalario Universitario de Ferrol (M.Á.L.-G.); Hospital Universitario Ramón y Cajal (L.C.-F.F.), Madrid; Hospital Universitario de la Princesa (V.M.L.), Madrid; Complejo Hospitalario Universitario de Albacete, (E.F.D.); Hospital Universitario Fundación Jiménez Díaz (I.M.T.), Madrid; Hospital General Universitario Gregorio Marañón (J.M.G.-D.), Madrid; Hospital La Mancha Centro (G.O.-S., Á.D.S.), Alcázar de San Juan; Hospital Universitario Príncipe de Asturias (L.A.P.), Alcalá de Henares; Hospital Universitario Infanta Leonor (M.G.M.), Madrid; Hospital Universitario Mútua Terrasa (J.J.S.-F.); Complejo Asistencial de Ávila (A.B.C.-R.), Ávila; Hospital Universitario de Fuenlabrada (L.A.R.A.), Madrid; Hospital Universitario Son Espases, Palma de Mallorca (M.C.S.); Complejo Hospitalario de Navarra (M.A.O.-M., T.A.B.), Pamplona; Hospital Universitario y Politécnico La Fe (F.C.P.-M.), Valencia; Hospital Regional Universitario de Málaga (V.R.G.); Hospital Universitario de Getafe (J.J.B.-G.), Madrid; Hospital Santa Barbara (M.M.P.), Puertollano; Hospital Virgen de la Salud (I.P.M.), Toledo; Hospital Universitario Virgen de las Nieves (C.A.G.), Granada; Hospital Universitario Puerta del Sur (CINAC), Madrid (C.G.C.); Hospital Clínico Universitario Zaragoza (C.Í.M.), Zaragoza; Hospital Clínico Universitario Valladolid (N.T.L.,), Valladolid; Hospital Virgen del Puerto (F.C.P.), Plasencia; Hospital Universitario Donostia (T.C.T.), San Sebastian; Hospital General de Segovia (D.M.C.-S.), Segovia; Hospital General Universitario de Alicante (Á.P.S.), Alicante; Hospital Universitario Miguel Servet (IIS Aragón) (B.S.T.), Zaragoza; Hospital Universitario Araba (A.Á.A.), Vitoria; Hospital Clínico Universitario de Santiago de Compostela (E.C.A.), Santiago de Compostela; Hospital Universitario Juan Ramón Jiménez (E.D.-F.), Huelva; Hospital de Terrasa (M.F.M.), Terrasa; Hospital Universitario de Canarias (M.G.P.), San Cristobal de La Laguna; Hospital Universitario Dr Peset de Valencia (L.L.P.), Valencia; Complejo Hospitalario Universitario de Cartagena (J.M.P.), Murcia; Hospital Clínico San Carlos (C.O.-G.),Facultad de Medicina, Universidad Complutense de Madrid, IdISSC, Madrid; and CSUR Unidad de Esclerosis Múltiple y Neuroinmunología Clínica (J.E.M.-L.), Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Cátedra de Esclerosis Múltiple y Neuroinmunología Clínica, UCAM, Universidad Católica San Antonio, Murcia, Spain.
Objective: To understand COVID-19 characteristics in people with multiple sclerosis (MS) and identify high-risk individuals due to their immunocompromised state resulting from the use of disease-modifying treatments.
Methods: Retrospective and multicenter registry in patients with MS with suspected or confirmed COVID-19 diagnosis and available disease course (mild = ambulatory; severe = hospitalization; and critical = intensive care unit/death). Cases were analyzed for associations between MS characteristics and COVID-19 course and for identifying risk factors for a fatal outcome.
Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement.
Neurologia (Engl Ed)
September 2021
Servicio de Neurología, Hospital Moises Broggi y Hospital General de L'Hospitalet, Hospitalet de Llobregat, Barcelona, España.
Background: The recent development of highly effective treatments for multiple sclerosis (MS) and the potential risk of infectious complications require the development of prevention and risk minimisation strategies. Vaccination is an essential element of the management of these patients. This consensus statement includes a series of recommendations and practical scenarios for the vaccination of adult patients with MS who are eligible for highly effective immunosuppressive treatments.
View Article and Find Full Text PDFConsensus statement on the use of alemtuzumab in daily clinical practice in Spain.
Neurologia (Engl Ed)
October 2022
Centro de Esclerosis Múltiple de Cataluña (Cemcat), Servicio de Neurología/Neuroinmunología, Hospital Universitario Vall de Hebrón, Barcelona, España.
Introduction: Alemtuzumab is a highly effective drug approved by the European Medicines Agency as a disease-modifying drug for the treatment of relapsing-remitting multiple sclerosis.
Objective: A consensus document was drafted on the management of alemtuzumab in routine clinical practice in Spain.
Development: A group of multiple sclerosis specialists reviewed articles addressing treatment with alemtuzumab in patients with multiple sclerosis and published before December 2017.